指南与共识中毒与环境急症心脑血管急症消化、代谢与肾脏急症

过量服用非处方左甲状腺素钠片致迁延性心脏毒性甲状腺毒症一例并政策建议

[THYROTOXICOSIS WITH PROLONGED CARDIAC EFFECT DUE TO EXCESS LIOTHYRONINE CONSUMPTION 'OVER THE COUNTER': A CASE REPORT AND RECOMMENDATIONS FOR POLICY MAKERS].
指南 / 共识 · Harefuah · 2025-01-01
一句话结论一例33岁肥胖男性因服用含碘塞罗宁(135 µg/片)的「减肥」非处方产品5天,出现宽QRS波心动过速和胸痛的严重甲状腺毒症,停药并予胺碘酮和考来烯胺后恢复,作者建议尽快完善此类产品监管。

本文报告一例33岁肥胖男性(BMI=40 kg/m2),无甲状腺疾病史,因听信非注册「营养师」建议,服用含碘塞罗宁(135 µg/片)的「减肥」膳食补充剂5天,出现宽QRS波心动过速和胸痛等严重甲状腺毒症表现。内分泌检查示TSH和游离T4降低、游离T3升高。停用该药后,在FT3结果回报前开始短期胺碘酮治疗并联合考来烯胺,ICU治疗3天后心率稳定、FT3显著下降。随访超声心动图显示临界性左心室功能不全,出院后4年TSH正常。以色列卫生部随后发布警告,作者呼吁尽快完善此类产品监管。

要点

  • 无甲状腺疾病者服用含碘塞罗宁(135 µg/片)的「减肥」非处方产品5天,可出现宽QRS波心动过速、胸痛及TSH和游离T4降低、游离T3升高的严重甲状腺毒症。
  • 该例在FT3结果回报前开始短期胺碘酮治疗,并联合考来烯胺,同时停用含碘塞罗宁片。
  • ICU治疗3天后心率稳定、FT3显著下降;随访超声心动图显示临界性左心室功能不全,出院后4年TSH正常。
  • 产品由非注册人员以「减肥」膳食补充剂名义提供,无医学检查或适应证;以色列卫生部(MOH)随后在网站发布警告,建议公众避免这些片剂。
  • 作者认为,非处方「减肥」产品需求增加、链条监管执法不足、产品宣传方式及非授权人员销售的可能性,凸显尽快完善监管的必要性。

适用人群与场景

  • 无甲状腺疾病史、因服用含碘塞罗宁的非处方「减肥」产品而出现甲状腺毒症表现者;本例为33岁肥胖男性(BMI=40 kg/m2)。
  • 本例住院前未接触含碘造影剂,也未服用胺碘酮等含碘药物。

诊断标准与关键阈值

  • 甲状腺毒症经内分泌检查确认:TSH和游离T4降低、游离T3(FT3)升高。

处置流程与药物剂量

  • 停用含碘塞罗宁(135 µg/片)的片剂。
  • 在FT3结果回报前开始短期胺碘酮治疗,并联合考来烯胺。
  • 收入ICU治疗3天后心率稳定、FT3显著下降。

红旗征与不能漏的情况

  • 宽QRS波心动过速和胸痛,提示严重甲状腺毒症的心脏表现。
  • 随访超声心动图显示临界性左心室功能不全。

研究设计与关键结果

  • 病例报告:33岁肥胖男性(BMI=40 kg/m2)无甲状腺疾病,服用含碘塞罗宁(135 µg/片)的「减肥」膳食补充剂5天后出现宽QRS波心动过速和胸痛,内分泌检查示TSH和游离T4降低、FT3升高。
  • 停用片剂并予短期胺碘酮(在FT3结果回报前开始)联合考来烯胺,ICU治疗3天后心率稳定、FT3显著下降。
  • 随访超声心动图显示临界性左心室功能不全;出院后4年TSH正常。
  • 以色列卫生部(MOH)在调查后于网站发布警告,建议公众避免这些片剂。

证据类型、等级与局限

  • 证据类型:病例报告及政策建议。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对无甲状腺疾病而出现严重甲状腺毒症表现(如宽QRS波心动过速、胸痛)者,应询问非处方「减肥」产品服用史,本例产品含碘塞罗宁135 µg/片。
  • 本例在FT3结果回报前开始短期胺碘酮并联合考来烯胺,同时停用含碘塞罗宁片剂,ICU治疗3天后心率稳定、FT3显著下降。
  • 作者认为,非处方「减肥」产品需求增加、监管执法不足及非授权人员销售的可能性,凸显尽快完善监管的必要性。

指南或共识出处

  • Harefuah

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Exogenous excessive thyroid hormone intake may result in severe thyrotoxicosis and might be harmful to human health. In spite of this, a growing number of people consume over-the-counter (OTC) products that also contain Triiodothyronine (T3) and Thyroxine (T4). We report a case of Liothyronine-containing tablets consumption causing T3-induced thyrotoxicosis. A 33-year-old obese man (BMI=40 kg/m2) with no thyroid disease had typical signs of substantial thyrotoxicosis (including wide complex tachycardia and chest pain), which were confirmed by endocrine tests: both low thyrotropin (TSH) and free T4 as well as elevated free T3 (FT3). Prior to hospitalization, he had not been exposed to iodinated radiocontrast media and had not taken medications containing iodine, such as amiodarone. However, we discovered that the patient consumed tablets containing Liothyronine (135 µg/tablet) for five days prior to hospitalization following the suggestion of a non-registered individual, who introduced himself as a nutritionist. The tablets were misleadingly presented to the patient as a "weight loss" dietary supplement. The tablets were discontinued and a short term therapy that included Amiodarone (before FT3 arrived) was initiated along with Cholestyramine. After three days in the intensive care unit, the patient's heart rate stabilized and his FT3 level decreased substantially. Following investigations, the Israeli Ministry of Health (MOH) published a warning on its website advising the public to avoid these tablets. After follow-up in the community, a repeat echocardiogram revealed a borderline left ventricle dysfunction. During the four years since the patient was released from our hospital, his TSH levels have been normal.

CONCLUSIONS: Liothyronine consumption has been associated with substantial thyrotoxicosis and cardiac damage. The Liothyronine tablets were provided to the patient by an unauthorized party, as a weight losing nutritional supplement. However, this was done without a medical examination or indication. The increase in demand for "weight-losing" products 'over the counter', the lack of effective enforcement in the chain, the way these products are presented and the possibility of those who are not authorized to market and supply them, emphasize the need to settle the regulation of this issue as soon as possible.

来源:Harefuah,查看原文。版权归原作者所有。

参考来源

  1. Ovadia YS, Paley L, Berkovitz R, et al. [THYROTOXICOSIS WITH PROLONGED CARDIAC EFFECT DUE TO EXCESS LIOTHYRONINE CONSUMPTION 'OVER THE COUNTER': A CASE REPORT AND RECOMMENDATIONS FOR POLICY MAKERS]. Harefuah. 2025. PMID: 40530630

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。